Walmart Statement on the Sale of Ranitidine Products
October 02 2019 - 8:30AM
Business Wire
Walmart Inc. is suspending the sale of all over the counter
ranitidine products in stores, clubs and online, including Zantac,
Equate and Member’s Mark brands.
The company is taking this action after closely monitoring the
recent Product Alert from the U.S. Food and Drug Administration
(FDA) that ranitidine products may contain a low level of
nitrosodimethylamine (NDMA). Customers who purchased these products
may return them to Walmart or Sam’s Club for a refund.
Additional details on NDMA in ranitidine are available through
the FDA.
About Walmart Walmart Inc. (NYSE: WMT) helps people
around the world save money and live better - anytime and anywhere
– in retail stores, online, and through their mobile devices. Each
week, nearly 275 million customers and members visit our more than
11,300 stores under 58 banners in 27 countries and eCommerce
websites. With fiscal year 2019 revenue of $514.4 billion, Walmart
employs over 2.2 million associates worldwide. Walmart continues to
be a leader in sustainability, corporate philanthropy and
employment opportunity. Additional information about Walmart can be
found by visiting http://corporate.walmart.com, on Facebook at
http://facebook.com/walmart and on Twitter at
http://twitter.com/walmart.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191002005455/en/
Erin Hulliberger, Walmart Media Relations 1-800-331-0085,
http://news.walmart.com/reporter
Walmart (NYSE:WMT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Walmart (NYSE:WMT)
Historical Stock Chart
From Apr 2023 to Apr 2024